Log In
BCIQ
Print this Print this
 

AT132 (formerly AT001)

  Manage Alerts
Collapse Summary General Information
Company Audentes Therapeutics Inc.
DescriptionAdeno-associated viral serotype8 (AAV8) vector delivering the myotubularin 1 (MTM1) gene
Molecular Target
Mechanism of ActionGene therapy
Therapeutic ModalityGene therapy: Viral vector: Adeno-associated virus (AAV)
Latest Stage of DevelopmentPreclinical
Standard Indication Musculoskeletal (unspecified)
Indication DetailsTreat X-linked myotubular myopathy
Regulatory Designation U.S. - Orphan Drug (Treat X-linked myotubular myopathy);
EU - Orphan Drug (Treat X-linked myotubular myopathy)
PartnerGenethon

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

02/10/2014

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today